CAJ | 학술논문

目的观察并比较脑胶质母细胞瘤放疗加化疗与不加化疗的疗效。方法试验组28例患者放射治疗20～40 Gy后，加用化疗药洛莫司汀(CCNU)或卡莫司汀(BCNU)；对照组28例单纯放射治疗20～40 Gy，不加化疗药。结果经随访，试验组和对照组1，3，5年生存率分别为57.1%,22.5%,15.0%和17.9%,7.1%,3.6%, 中位生存期分别为29.7±7.0个月和9.7±3.5个月，P＜0.001,差异有极显著性。显示试验组疗效优于对照组。结论脑瘤放疗20～40 Gy后，血脑屏障开放，是化疗最佳时机，这期间加化疗，可显著提高生存率。
목적관찰병비교뇌효질모세포류방료가화료여불가화료적료효。방법시험조28례환자방사치료20～40 Gy후，가용화료약락막사정(CCNU)혹잡막사정(BCNU)；대조조28례단순방사치료20～40 Gy，불가화료약。결과경수방，시험조화대조조1，3，5년생존솔분별위57.1%,22.5%,15.0%화17.9%,7.1%,3.6%, 중위생존기분별위29.7±7.0개월화9.7±3.5개월，P＜0.001,차이유겁현저성。현시시험조료효우우대조조。결론뇌류방료20～40 Gy후，혈뇌병장개방，시화료최가시궤，저기간가화료，가현저제고생존솔。
Objective　To study the efficacy of chemotherapy for glioblastoma on the basis of brain irradiation.　Methods　It was previously reported that the permeability of the blood brain barrier (BBB) to methotrexate could be increased by brain irradiation. In this study, glioblastoma patients were divided into 2 groups, 28 patients in each group. On group of patients was treated with CCNU or BCNU after having given 20～40 Gy irradiation to the brain. The other group of patients received radiation treatment alone.　Results　The 1-, 3-, and 5-year survival rate of the two groups of patients was 57.1%, 22.5%, 15.0% and 17.9%, 7.1%, 3.6%, respectively. The median survival time was 29.7±7.0 and 9.7±3.5 months, respectively (P＜0.001).　Conclusion　Inc-rease in permeability of the BBB after 20～40 Gy brain irradiation may provide an optimal chance for intracranial chemotherapy of glioblastoma.